Compare Johnson & Johnson (JNJ) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Charles Schwab Corporation Common Stock — how do they compare? Johnson & Johnson trades at $260.72 (market cap $618.09B), while Charles Schwab Corporation Common Stock trades at $96.68 (market cap $167.52B). The key difference: Johnson & Johnson is far larger — about 3.7× Charles Schwab Corporation Common Stock's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Charles Schwab Corporation Common Stock for 85 Days on average.
| JNJ | SCHW | |
|---|---|---|
Market Cap | $618.09B | $167.52B |
Volume | 6,050,983 | 6,554,126 |
Sector | Health | Financials |
52-Week High | $278.43 | $113.65 |
52-Week Low | $186.00 | $85.35 |
Typical Hold Time | 129 Days | 85 Days |
Enterprise Value | $646.37B | $153.97B |
Dividend Yield | 2.09% | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Charles Schwab (SCHW) trades at $96.80, up 1.28% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 17.64, net income margin of 38.79%, and robust cash flow. Recent news highlights growth in client assets to $13.41 trillion and a strategic AI partnership with Anthropic.
The outlook is positive with a consensus price target of $120.33, implying significant upside. Risks include competitive pressures and market volatility, but strong earnings momentum and a favorable industry growth forecast support a bullish case for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
